Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Study Analyzed Long-Term SYMBICORT(R) Use in Children With Persistent Asthma
April 4th, 2008
A new study analyzed long-term use of the maintenance combination asthma therapy, SYMBICORT(R) (budesonide/formoterol fumarate dihydrate), in treating persistent asthma in children 6 to 11 years old. The study examined the safety of SYMBICORT in children for 26 weeks and also included efficacy measures. For children previously treated with inhaled corticosteroid, either alone or in combination, the study showed that long-term treatment with SYMBICORT resulted in significantly greater improvements in lung function and reduced healthcare resource utilization, compared with budesonide dry powder inhaler (DPI) alone. In the study, SYMBICORT also had a safety profile similar to its...
Source: Health Business Week (2008-04-04)
|
